These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

709 related items for PubMed ID: 11705863

  • 1. Expression levels of the nerve growth factor receptors TrkA and p75 in effusions and solid tumors of serous ovarian carcinoma patients.
    Davidson B, Lazarovici P, Ezersky A, Nesland JM, Berner A, Risberg B, Tropé CG, Kristensen GB, Goscinski M, van de Putte G, Reich R.
    Clin Cancer Res; 2001 Nov; 7(11):3457-64. PubMed ID: 11705863
    [Abstract] [Full Text] [Related]

  • 2. Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma.
    Davidson B, Reich R, Lazarovici P, Nesland JM, Skrede M, Risberg B, Tropé CG, Flørenes VA.
    Clin Cancer Res; 2003 Jun; 9(6):2248-59. PubMed ID: 12796393
    [Abstract] [Full Text] [Related]

  • 3. Altered expression and activation of the nerve growth factor receptors TrkA and p75 provide the first evidence of tumor progression to effusion in breast carcinoma.
    Davidson B, Reich R, Lazarovici P, Ann Flørenes V, Nielsen S, Nesland JM.
    Breast Cancer Res Treat; 2004 Jan; 83(2):119-28. PubMed ID: 14997042
    [Abstract] [Full Text] [Related]

  • 4. The activated nerve growth factor receptor p-TrkA is selectively expressed in advanced-stage ovarian carcinoma.
    Ødegaard E, Staff AC, Abeler VM, Kopolovic J, Onsrud M, Lazarovici P, Davidson B.
    Hum Pathol; 2007 Jan; 38(1):140-6. PubMed ID: 16996570
    [Abstract] [Full Text] [Related]

  • 5. Expression of the nerve growth factor receptors TrkA and p75 in malignant mesothelioma.
    Davidson B, Reich R, Lazarovici P, Flørenes VA, Risberg B, Nielsen S, Sert B, Bedrossian C.
    Lung Cancer; 2004 May; 44(2):159-65. PubMed ID: 15084380
    [Abstract] [Full Text] [Related]

  • 6. Expression of nerve growth factor receptors and their prognostic value in human pancreatic cancer.
    Zhang Y, Dang C, Ma Q, Shimahara Y.
    Oncol Rep; 2005 Jul; 14(1):161-71. PubMed ID: 15944784
    [Abstract] [Full Text] [Related]

  • 7. Expression of cell cycle proteins in ovarian carcinoma cells in serous effusions-biological and prognostic implications.
    Davidson B, Risberg B, Berner A, Nesland JM, Tropé CG, Kristensen GB, Bryne M, Goscinski M, van de Putte G, Flørenes VA.
    Gynecol Oncol; 2001 Nov; 83(2):249-56. PubMed ID: 11606079
    [Abstract] [Full Text] [Related]

  • 8. Expression of the peroxisome proliferator-activated receptors-alpha, -beta, and -gamma in ovarian carcinoma effusions is associated with poor chemoresponse and shorter survival.
    Davidson B, Hadar R, Stavnes HT, Trope' CG, Reich R.
    Hum Pathol; 2009 May; 40(5):705-13. PubMed ID: 19157507
    [Abstract] [Full Text] [Related]

  • 9. Nerve growth factor exerts differential effects on the growth of human pancreatic cancer cells.
    Zhu ZW, Friess H, Wang L, Bogardus T, Korc M, Kleeff J, Büchler MW.
    Clin Cancer Res; 2001 Jan; 7(1):105-12. PubMed ID: 11205897
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma.
    Gorovetz M, Baekelandt M, Berner A, Trope' CG, Davidson B, Reich R.
    Gynecol Oncol; 2006 Dec; 103(3):831-40. PubMed ID: 16919315
    [Abstract] [Full Text] [Related]

  • 12. Kallikrein 4 expression is up-regulated in epithelial ovarian carcinoma cells in effusions.
    Davidson B, Xi Z, Klokk TI, Tropé CG, Dørum A, Scheistrøen M, Saatcioglu F.
    Am J Clin Pathol; 2005 Mar; 123(3):360-8. PubMed ID: 15716231
    [Abstract] [Full Text] [Related]

  • 13. Angiogenic molecule expression is downregulated in effusions from breast cancer patients.
    Konstantinovsky S, Nielsen S, Vyberg M, Kvalheim G, Nesland JM, Reich R, Davidson B.
    Breast Cancer Res Treat; 2005 Nov; 94(1):71-80. PubMed ID: 16142438
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Expression of membrane-type 1, 2, and 3 matrix metalloproteinases messenger RNA in ovarian carcinoma cells in serous effusions.
    Davidson B, Goldberg I, Berner A, Nesland JM, Givant-Horwitz V, Bryne M, Risberg B, Kristensen GB, Tropé CG, Kopolovic J, Reich R.
    Am J Clin Pathol; 2001 Apr; 115(4):517-24. PubMed ID: 11293899
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. E-cadherin and alpha-, beta-, and gamma-catenin protein expression is up-regulated in ovarian carcinoma cells in serous effusions.
    Davidson B, Berner A, Nesland JM, Risberg B, Berner HS, Tropè CG, Kristensen GB, Bryne M, Ann Florenes V.
    J Pathol; 2000 Dec; 192(4):460-9. PubMed ID: 11113863
    [Abstract] [Full Text] [Related]

  • 18. Type IV collagen and CD44v6 expression in benign, malignant primary and metastatic ovarian tumors: correlation with Ki-67 and p53 immunoreactivity.
    Bar JK, Grelewski P, Popiela A, Noga L, Rabczyñski J.
    Gynecol Oncol; 2004 Oct; 95(1):23-31. PubMed ID: 15385106
    [Abstract] [Full Text] [Related]

  • 19. HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma.
    Davidson B, Elstrand MB, McMaster MT, Berner A, Kurman RJ, Risberg B, Trope CG, Shih IeM.
    Gynecol Oncol; 2005 Jan; 96(1):42-7. PubMed ID: 15589578
    [Abstract] [Full Text] [Related]

  • 20. MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells.
    Davidson B, Baekelandt M, Shih IeM.
    Diagn Cytopathol; 2007 Dec; 35(12):756-60. PubMed ID: 18008338
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.